These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21193441)

  • 1. Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
    Van Assche G
    Gut; 2011 Mar; 60(3):285-6. PubMed ID: 21193441
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapies of chronic inflammatory bowel disease: anti-TNF antibodies and probiotics. The Danish Society of Gastroenterology].
    Kjeldsen J; Brynskov J; Madsen JR
    Ugeskr Laeger; 2001 Mar; 163(12):1707. PubMed ID: 11284407
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
    Allez M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 10. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of infliximab in Crohn's disease.
    Hanauer SB
    N Engl J Med; 2003 May; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical treatment of inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 16. Investigation of the functional characteristics of antibodies to therapeutic anti-human tumor necrosis factor alpha monoclonal antibody.
    Yucel A; Aral AL; Basturk B; Karakus R; Aybay C; Aybay C
    Immunol Lett; 2007 Aug; 111(2):84-91. PubMed ID: 17618693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour necrosis factor and inflammatory bowel disease.
    Armstrong AM; Gardiner KR; Kirk SJ; Halliday MI; Rowlands BJ
    Br J Surg; 1997 Aug; 84(8):1051-8. PubMed ID: 9278640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in inflammatory disease: infliximab associated risk of lymphoma development.
    Bucher C; Degen L; Dirnhofer S; Pless M; Herrmann R; Schraml P; Went P
    Gut; 2005 May; 54(5):732-3. PubMed ID: 15831931
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-TNF treatment in Crohn's disease: toward tailored therapy?
    D'Haens G
    Am J Gastroenterol; 2010 May; 105(5):1140-1. PubMed ID: 20445512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.